

Itw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/787,417 Confirmation No.: 4537
Applicant: Chien-Hsuan HAN et al.
Filed: February 27, 2004
TC/Art Unit: 1615
Examiner: H. SHEIKH
Docket No.: 49393-00004
Customer No.: 23767

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56(b)

Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. § 1.56. Copies of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §§ 1.97-1.98.

The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against claims of the present application.

The Information Disclosure Statement is being filed prior to the mailing of the first Office Action. Accordingly, it is believed that no fee is due at this time.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. § 609.


Serial No. 10/787,417

Atty. Docket No. 49393-00004

The Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this paper to undersigned's Deposit Account No. 50-1067.


Respectfully submitted,

August 31, 2004



Lawrence M. Sung
Reg. No. 38,330

Preston Gates Ellis & Rouvelas Meeds LLP
1735 New York Avenue, NW, Suite 500
Washington, DC 20006
Telephone: 202.628.1700
Facsimile: 202.331.1024



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/787,417	
			Filing Date	February 27, 2004	
			First Named Inventor	Chien-Hsuan HAN	
			Art Unit	1615	
			Examiner Name	H. SHEIKH	
Sheet	1	of	3	Attorney Docket Number	49393-00004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	ATTWELL, ET AL., "EFFECT OF CARBIDOPA DOSE ON PHARMACOKINETIC AND METABOLIC HANDLING OF AN ORAL BOLUS OF L-DOPA IN RATS," BRITISH JOURNAL OF PHARMACOLOGY (1990), 101:496P.	
	B2	BENABOU, ET AL., "HEPATOTOXIC PROFILE OF CATECHOL-O-METHYLTRANSFERASE INHIBITORS IN PARKINSON'S DISEASE," EXPERT OPIN. DRUG SAF. (2003), 2(3): 263-267.	
	B3	BERGSTROM, ET AL., "CATECHOL-O-METHYLTRANSFERASE INHIBITION INCREASES THE UPTAKE OF ¹¹ C-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE IN THE RAT PANCREAS," SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (1996), 31(12): 1216-1222.	
	B4	BREDBERG, ET AL., "PHARMACOKINETICS OF LEVODOPA AND CARBIDOPA IN RATS FOLLOWING DIFFERENT ROUTES OF ADMINISTRATION," PHARMACEUTICAL RESEARCH (1994), 11(4): 549-555.	
	B5	FODALE, ET AL., "DRUGS OF ANESTHESIA, CENTRAL NICOTINIC RECEPTORS AND PARKINSON'S DISEASE," PARKINSONISM AND RELATED DISORDERS (2004), 10: 189-190.	
	B6	FORSBERG, ET AL., "PHARMACOKINETICS AND PHARMACODYNAMICS OF ENTACAPONE AND TOLCAPONE AFTER ACUTE AND REPEATED ADMINISTRATION: A COMPARATIVE STUDY IN THE RAT," THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003), 304(2): 498-506.	
	B7	HENCHCLIFFE, ET AL., "ENTACAPONE IN THE MANAGEMENT OF PARKINSON'S DISEASE," EXPERT OPIN. PHARMACOTHER. (2002), 3(7): 957-963.	
	B8	ICHIKAWA, ET AL., "PHARMACOLOGICAL EFFECTS OF CABERGOLINE AGAINST PARKINSONISM," FOLIA PHARMACOL. JAPAN (2001), 117: 395-400.	√
	B9	KARABAN, ET AL., "THE USE OF AMANTADINE SULFATE IN COMBINED THERAPY OF PARKINSON'S DISEASE," ZH NEVROL PSIKHIATR IM S S KORSKOVA (2002), 102(7): 20-4.	√

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/787,417
				Filing Date	February 27, 2004
				First Named Inventor	Chien-Hsuan HAN
				Art Unit	1615
				Examiner Name	H. SHEIKH
Sheet	2	of	3	Attorney Docket Number	49393-00004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	B10	KULISEVSKY, ET AL., "ENTACAPONE: IS IT USEFUL AS COMPLEMENTARY TREATMENT WITH LEVODOPA?" REV. NEUROL. (1999), 28(8): 817-834.			✓
	B11	KUPSCH, ET AL., "LEVODOPA THERAPY WITH ENTACAPONE IN DAILY CLINICAL PRACTICE: RESULTS OF A POST-MARKETING SURVEILLANCE STUDY," CURRENT MEDICAL RESEARCH AND OPINION (2004), 20(1): 115-120.			
	B12	LEES, ET AL., "SUBLINGUAL APOMORPHINE AND PARKINSON'S DISEASE," JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY (1989), 52(12): 1440.			
	B13	LOPEZ LOZANO, ET AL., "PREPARATION OF A LEVODOPA/CARBIDOPA SOLUTION IN ASCORBIC ACID (CITRIDOPA) AND CHROMATOGRAPHIC AND ELECTROCHEMICAL ASSESSMENT OF ITS STABILITY OVER 24 HOURS," NEUROLOGIA (APRIL, 1995), 10(4): 155-158.			✓
	B14	MONTASTRUC, ET AL., "BROMOCRIPTINE VERSUS LEVODOPA IN THE EARLY TREATMENT OF PARKINSON'S DISEASE. 1 ST RESULTS AFTER 2 YEARS," THERAPIE (OCT-DEC 1988), 43(6): 461-3.			✓
	B15	MONTASTRUC, ET AL., "COMPARISON OF BROMOCRIPTINE AND LEVODOPA AS FIRST LINE TREATMENT OF PARKINSON'S DISEASE: RESULTS OF A 3-YEAR PROSPECTIVE RANDOMIZED STUDY," REV. NEUROL. (PARIS) (1990), 146(2): 144-7.			✓
	B16	MONTASTRUC, ET AL., "A PILOT STUDY OF N-METHYL-D-ASPARTATE (NMDA) ANTAGONIST IN PARKINSON'S DISEASE," JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY (1992), 55(7): 630-631.			
	B17	RASCOL, "DATA IN FAVOR OF DOPAMINERGIC AGONISTS ONLY," REV. NEUROL. (PARIS) (1999), 155(1): 35-42.			✓
	B18	REICHMANN, ET AL., "PRAMIPEXOL BEI DER PARKINSON-KRANKHEIT: ERGEBNISSE EINER ANWENDUNGSBEOBACHTUNG," DER NERVENARZT (AUGUST 2002), 73: 745-750.			✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/787,417
				Filing Date	February 27, 2004
				First Named Inventor	Chien-Hsuan HAN
				Art Unit	1615
				Examiner Name	H. SHEIKH
Sheet	3	of	3	Attorney Docket Number	49393-00004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	B19	ROSE, ET AL., "THE EFFECT OF CARBIDOPA ON THE PHARMACOKINETICS OF L-DIHYDROXYPHENYLALANINE IN THE RAT," EUROPEAN JOURNAL OF PHARMACOLOGY (1990), 183(3): 968-969.		
	B20	SANTENS, "SLEEP ATTACKS IN PARKINSON'S DISEASE INDUCED BY ENTACAPONE, A COMT-INHIBITOR," FUNDAMENTAL & CLINICAL PHARMACOLOGY (2003), 17: 121-123.		
	B21	SHUTO, ET AL., "(1S,2R)-1-PHENYL-2-[(S)-1-AMINOPROPYL]-N, N-DIETHYLCYCLOPROPANE-CARBOXAMIDE (PPDC), A NEW CLASS OF NMDA-RECEPTOR ANTAGONIST: MOLECULAR DESIGN BY A NOVEL CONFORMATIONAL RESTRICTION STRATEGY," JPN. J. PHARMACOL. (2001), 85: 207-213.		
	B22	SMITH, ET AL., "IN VITRO METABOLISM OF TOLCAPONE TO REACTIVE INTERMEDIATES: RELEVANCE TO TOLCAPONE LIVER TOXICITY," CHEM. RES. TOXICOL. (2003), 16(2): 123-128.		
	B23	WIKBERG, ET AL., "IDENTIFICATION OF MAJOR URINARY METABOLITES OF THE CATECHOL-O-METHYLTRANSFERASE INHIBITOR ENTACAPONE IN THE DOG," EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (1993), 18(4): 359-367.		
	B24	"DA AGONISTS – NON-ERGOT DERIVATIVES: PRAMIPEXOLE," MOVEMENT DISORDERS (2002), 17(SUPP 4): S93-S97.		
	B25	CARBIDOPA AND LEVODOPA TABLETS, PRODUCT INSERT, SEPTEMBER 2001.		
	B26	CARBIDOPA, OFFICIAL MONOGRAPHS, U.S. PHARMACOPEIA 26, PP. 328-329.		
	B27	LODOSYN ® (CARBIDOPA) TABLETS, PHYSICIANS' DESK REFERENCE, 57 TH EDITION (2003), PP. 1090-1092.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.